Close Menu

NEW YORK – Oncocyte announced on Friday it has reached definitive agreements with institutional investors that will purchase about $10.7 million of the company's common shares in a registered offering.

The investors, which include Blackcrane Capital, will purchase the shares at an at-the-market price of $2.27 per share, the closing price of Oncocyte's stock immediately preceding the offering. Oncocyte is selling about 4.7 million shares in the offering, which is expected to close next week.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.